Since the enactment of the Hatch-Waxman Act in 1984, courts have held that brand companies can sue generics wherever they plan on making sales, which is everywhere in the U.S. In practice, most suits have been filed in Delaware and New Jersey, with suits against multiple generic companies over the same drug consolidated in one proceeding.
In November 2020, the Federal Circuit upended this settled practice when it issued its opinion in Valeant Pharmaceuticals v. Mylan Pharmaceuticals, No. 19-2402 (Fed. Cir. 2020), holding that venue is not established by contemplated future acts of ...
Blog Editors
Recent Updates
- U.S. Judicial Conference Aims to Curb "Judge Shopping": New Guidance Promoting Random Civil Case Assignments
- Insignificant Harm Not So Insignificant in Proving Title VII Transfer Violation - SCOTUS Today
- Today’s Argument Was More Consequential Than Issued Opinions - SCOTUS Today
- Supreme Court Underscores Limited Applicability of Rule 10b-5(b) Omissions Claims
- Unanimity Among Justices Rules the Day - SCOTUS Today